Michael P. Weiner

RainDance Technologies, Inc. engages in the development and commercialization of professional laboratory system. It develops and manufactures genomic tools for non-invasive liquid biopsy applications for the research, early detection, treatment of cancer, and inherited and infectious diseases. The company was founded by Andrew Griffiths, Darren R. Link, and Jerome Bibette in 2004 and is headquartered in Billerica, MA.

Affomix Corp. was develops and commercializes antibody based products. The company was founded in 2008 and headquartered in Branford, CT.

GnuBIO, Inc. develops life science research and clinical diagnostics products. It develops a droplet-based DNA sequencing technology that integrates the entire sample preparation workflow on a chip, from sample capture, PCR, and sequencing to informatics for researchers and clinicians. The company was founded by David A. Weitz, John J. Boyce, IV and Michael P. Weiner and is headquartered in Cambridge, MA.

AxioMx, Inc. develops and produces recombinant antibody technologies. Its service offerings include antigen & project design, recombinant antibody development, antibody optimization, and antibody production. The company was founded by Christopher K. McLeod and Michael P. Weiner in 2012 and is headquartered in Branford, CT.

GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada.

454 Life Sciences Corp. engages in the provision of medical testing services to determine the nucleotide sequence of whole genomes. The company was founded by Jonathan M. Rothberg in 2000 and is headquartered in Branford, CT.

Abbratech, Inc. is a biotechnology company that focuses on precision antibodies. Abbratech is based in Branford, CT. The company offers services such as antigen and project design, recombinant antibody development, antibody optimization, and antibody production. Abbratech uses the best available in vivo and in vitro methods for antibody discovery and applies knowledge gained from the past 15 years of human genome sequencing and antibody engineering to produce high affinity and highly specific recombinant antibodies. The company was founded in 2020 by Michael P. Weiner, who has been the CEO since then.